Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CTHRC-1 monoclonal antibody
- Development stage
- Preclinical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
CTHRC-1 monoclonal antibody is an experimental biologic therapeutic designed to target the collagen triple helix repeat-containing protein 1 (CTHRC-1). CTHRC-1 is a secreted glycoprotein that is highly expressed in various cancers, including cervical, pancreatic, melanoma, and breast carcinoma, where it is associated with increased cell migration, invasion, and metastasis. The antibody works by binding to and neutralizing CTHRC-1, thereby inhibiting its ability to promote epithelial-mesenchymal transition (EMT) and wound healing in malignant cells. Preclinical research has demonstrated that this antibody can significantly attenuate the metastatic potential of cervical cancer cells in vitro and inhibit lung metastasis in vivo, suggesting its potential as a targeted therapy for advanced or metastatic malignancies.
- Other names
- anti-CTHRC-1 monoclonal antibodyanti-CTHRC1 monoclonal antibodyanti-CTHRC 1 monoclonal antibodyCTHRC1 mAbCTHRC-1 mAbCTHRC 1 mAb
02
Targets
CTHRC1 (Collagen triple helix repeat-containing protein 1)
Beyond the preview
Go deeper on CTHRC-1 monoclonal antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CTHRC-1 monoclonal antibody.